March 9, 2016 / 5:07 PM / a year ago

BRIEF-Genmab files for European approval of ofatumumab combination to treat leukemia

March 9 (Reuters) - Danish biotech company Genmab

* Says announces European regulatory submission for ofatumumab in combination with fludarabine and cyclophosphamide for relapsed CLL

* Says CLL is the most common form of leukemia in the Western world, accounting for 30 percent of adult leukemias

* Says application was submitted by Novartis under ofatumumab collaboration between Novartis and Genmab

* Says application is based on results from a phase III study

* Says top-line results from this trial were reported in April 2015 Source text for Eikon: Further company coverage: (Reporting by Copenhagen Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below